SCHEMBL4289485

SCHEMBL4289485

CC(=O)n1ncc2cc(-c3nnn(Cc4ccccc4)c3C)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 6/20 0.48
GSK3A P49840 6/20 0.48
PRKACA P17612 6/20 0.48
CDK2 P24941 6/20 0.48
CDC7 O00311 6/20 0.48
GSK3B P49841 5/20 0.48
MKNK2 Q9HBH9 5/20 0.48
ROCK2 O75116 5/20 0.48
CDK1 P06493 5/20 0.48
RPS6KA3 P51812 5/20 0.48
CDK5 Q00535 5/20 0.48
PRKCD Q05655 5/20 0.48
ROCK1 Q13464 5/20 0.48
DYRK1A Q13627 5/20 0.48
CDC42BPA Q5VT25 5/20 0.48
AURKB Q96GD4 5/20 0.48
PLK4 O00444 4/20 0.48
PRKX P51817 4/20 0.48
MAP4K2 Q12851 4/20 0.48
PRKG1 Q13976 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4285256 0.89 CDC7 (0.57) CLK4GSK3APRKACACDK2CDC7
SCHEMBL4291536 0.86 CDC7 (0.54) CLK4GSK3APRKACACDK2CDC7
SCHEMBL27788225 0.86 CLK4 (0.44) CLK4GSK3APRKACACDK2CDC7
SCHEMBL3669460 0.85 CLK4 (0.49) CLK4GSK3APRKACACDK2CDC7
SCHEMBL3664505 0.83 CDC7 (0.41) CLK4GSK3APRKACACDK2CDC7
SCHEMBL27788240 0.79 CDC7 (0.55) CLK4GSK3APRKACACDK2CDC7
SCHEMBL3668504 0.73 GSK3B (0.75) CLK4GSK3APRKACACDK2CDC7
SCHEMBL4289776 0.70 CDC7 (0.57) CLK4GSK3APRKACACDK2CDC7
SCHEMBL3632690 0.69 CDC7 (0.58) CLK4GSK3APRKACACDK2CDC7
SCHEMBL3917675 0.69 SRD5A2 (0.56) CLK4GSK3AROCK1DAPK3CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CLK4 260/4885GSK3A 2/4885PRKACA 178/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CLK4 260/4885GSK3A 2/4885PRKACA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.